Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

Combating Enhanced Intracellular Survival (Eis)-Mediated Kanamycin Resistance of Mycobacterium tuberculosis by Novel Pyrrolo[1,5-a]pyrazine-Based Eis Inhibitors

Producción científica: Article › revisión exhaustiva

53 Citas (Scopus)

Resumen

Tuberculosis (TB) remains one of the leading causes of mortality worldwide. Hence, the identification of highly effective antitubercular drugs with novel modes of action is crucial. In this paper, we report the discovery and development of pyrrolo[1,5-a]pyrazine-based analogues as highly potent inhibitors of the Mycobacterium tuberculosis (Mtb) acetyltransferase enhanced intracellular survival (Eis), whose up-regulation causes clinically observed resistance to the aminoglycoside (AG) antibiotic kanamycin A (KAN). We performed a structure-activity relationship (SAR) study to optimize these compounds as potent Eis inhibitors both against purified enzyme and in mycobacterial cells. A crystal structure of Eis in complex with one of the most potent inhibitors reveals that the compound is bound to Eis in the AG binding pocket, serving as the structural basis for the SAR. These Eis inhibitors have no observed cytotoxicity to mammalian cells and are promising leads for the development of innovative AG adjuvant therapies against drug-resistant TB.

Idioma originalEnglish
Páginas (desde-hasta)302-309
Número de páginas8
PublicaciónACS Infectious Diseases
Volumen3
N.º4
DOI
EstadoPublished - abr 14 2017

Nota bibliográfica

Publisher Copyright:
© 2017 American Chemical Society.

Financiación

This study was funded by a National Institutes of Health (NIH) Grant AI090048 (S.G.-T.) a grant from the Firland Foundation (S.G.-T.), a grant from the Center for Chemical Genomics (CCG) at the University of Michigan (S.G.-T) and startup funds from the College of Pharmacy at the University of Kentucky (S.G.-T. and O.V.T.). S.Y.L.H. is partially supported by a University of Kentucky Presidential Fellowship.

FinanciadoresNúmero del financiador
National Institutes of Health (NIH)
National Institute of Allergy and Infectious DiseasesR01AI090048
Firland Foundation
University of Michigan Hospital
University of Kentucky

    ODS de las Naciones Unidas

    Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

    1. Good health and well being
      Good health and well being

    ASJC Scopus subject areas

    • Infectious Diseases

    Huella

    Profundice en los temas de investigación de 'Combating Enhanced Intracellular Survival (Eis)-Mediated Kanamycin Resistance of Mycobacterium tuberculosis by Novel Pyrrolo[1,5-a]pyrazine-Based Eis Inhibitors'. En conjunto forman una huella única.

    Citar esto